Scancell (LON:SCLP) Hits New 1-Year Low – Time to Sell?

Scancell Holdings plc (LON:SCLP)’s share price reached a new 52-week low during trading on Thursday. The stock traded as low as GBX 88 and last traded at GBX 88, with a volume of 538,124 shares changing hands. The stock had previously closed at GBX 89.

Scancell Price Performance

The company has a quick ratio of 13.01, a current ratio of 0.28 and a debt-to-equity ratio of -88.01. The firm has a market capitalization of £1.20 billion, a price-to-earnings ratio of -160.71 and a beta of 0.69. The stock’s 50 day moving average price is GBX 95.16 and its two-hundred day moving average price is GBX 132.91.

Scancell (LON:SCLP) last announced its quarterly earnings data on Friday, October 9th. The company reported GBX (17.30) earnings per share (EPS) for the quarter. Scancell had a positive return on equity of 128.87% and a negative net margin of 116.98%. Analysts anticipate that Scancell Holdings plc will post -2.54 EPS for the current fiscal year.

About Scancell

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.